Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine.

Shi C, Washington K.

Am J Clin Pathol. 2012 Jun;137(6):847-59. doi: 10.1309/AJCPI83DINULUJNI.

PMID:
22586043
2.

Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer.

Kendall A, Lord R, Maisey N.

Recent Pat Anticancer Drug Discov. 2010 Jun;5(2):142-51. Review.

PMID:
19954416
3.

Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach.

Legolvan MP, Taliano RJ, Resnick MB.

Hum Pathol. 2012 Aug;43(8):1157-68. doi: 10.1016/j.humpath.2012.03.003. Epub 2012 Jun 1. Review.

PMID:
22658275
4.

Lynch syndrome screening in newly diagnosed colorectal cancer in general pathology practice: from the revised Bethesda guidelines to a universal approach.

Morrison J, Bronner M, Leach BH, Downs-Kelly E, Goldblum JR, Liu X.

Scand J Gastroenterol. 2011 Nov;46(11):1340-8. doi: 10.3109/00365521.2011.610003. Epub 2011 Aug 31.

PMID:
21879804
5.

BRAF mutation testing in colorectal cancer.

Sharma SG, Gulley ML.

Arch Pathol Lab Med. 2010 Aug;134(8):1225-8. doi: 10.1043/2009-0232-RS.1. Review.

PMID:
20670148
6.

Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics.

Imai K, Yamamoto H.

Carcinogenesis. 2008 Apr;29(4):673-80. Epub 2007 Oct 17. Review.

PMID:
17942460
7.

Recommendations to improve identification of hereditary and familial colorectal cancer in Europe.

Vasen HF, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, Blanco I, Bulow S, Burn J, Capella G, Colas C, Engel C, Frayling I, Rahner N, Hes FJ, Hodgson S, Mecklin JP, Møller P, Myrhøj T, Nagengast FM, Parc Y, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen J, Lubinski J, Järvinen H, Claes E, Heinimann K, Karagiannis JA, Lindblom A, Dove-Edwin I, Müller H.

Fam Cancer. 2010 Jun;9(2):109-15. doi: 10.1007/s10689-009-9291-3. Epub 2009 Sep 18.

PMID:
19763885
8.

Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer.

Amador ML, Hidalgo M.

Clin Colorectal Cancer. 2004 May;4(1):51-62. Review.

PMID:
15207021
9.
10.

Review article: The Lynch syndrome (hereditary nonpolyposis colorectal cancer).

Vasen HF.

Aliment Pharmacol Ther. 2007 Dec;26 Suppl 2:113-26. doi: 10.1111/j.1365-2036.2007.03479.x. Review.

12.

Lynch syndrome and MYH-associated polyposis: review and testing strategy.

Goodenberger M, Lindor NM.

J Clin Gastroenterol. 2011 Jul;45(6):488-500. doi: 10.1097/MCG.0b013e318206489c. Review.

PMID:
21325953
13.

[Prognostic role of KRAS mutation in colorectal cancer].

Di Fiore F, Michel P.

Bull Cancer. 2009 Dec;96 Suppl:S23-30. doi: 10.1684/bdc.2009.0994. French.

PMID:
20034867
14.

[Correlation between microsatellite instability and morphology in colorectal cancer].

Szentirmay Z, Gallai M, Serester O, Szoke J, Tóth E.

Magy Onkol. 2010 Jun;54(2):169-78. doi: 10.1556/MOnkol.54.2010.2.12. Hungarian.

15.

Predictive molecular classifiers in colorectal cancer.

Bohanes P, LaBonte MJ, Winder T, Lenz HJ.

Semin Oncol. 2011 Aug;38(4):576-87. doi: 10.1053/j.seminoncol.2011.05.012. Review.

PMID:
21810517
16.

KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?

Lopez-Crapez E, Mineur L, Emptas H, Lamy PJ.

Br J Cancer. 2010 Mar 16;102(6):1074-5; author reply 1076-7. doi: 10.1038/sj.bjc.6605582. Epub 2010 Feb 16. No abstract available.

17.

Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology.

Funkhouser WK Jr, Lubin IM, Monzon FA, Zehnbauer BA, Evans JP, Ogino S, Nowak JA.

J Mol Diagn. 2012 Mar-Apr;14(2):91-103. doi: 10.1016/j.jmoldx.2011.11.001. Epub 2012 Jan 17.

18.

Underutilization of microsatellite instability analysis in colorectal cancer patients at high risk for Lynch syndrome.

Van Lier MG, De Wilt JH, Wagemakers JJ, Dinjens WN, Damhuis RA, Wagner A, Kuipers EJ, Van Leerdam ME.

Scand J Gastroenterol. 2009;44(5):600-4. doi: 10.1080/00365520802706008.

PMID:
19153873
19.

Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.

Uribe P, Gonzalez S.

Pathol Res Pract. 2011 Jun 15;207(6):337-42. doi: 10.1016/j.prp.2011.03.002. Epub 2011 Apr 29. Review.

PMID:
21531084
20.

Detecting Lynch syndrome by pathologists.

van Krieken JH, Kets CM, Ligtenberg MJ, Hoogerbrugge N.

Verh Dtsch Ges Pathol. 2007;91:104-11.

PMID:
18314603

Supplemental Content

Support Center